Intracranial hemorrhage remains a devastating disease. Among
antiplatelet drugs,
cilostazol, a
phosphodiesterase 3 inhibitor, was recently reported to prevent secondary
hemorrhagic stroke in patients in a clinical trial. The aim of this study was to evaluate whether pre-treatment with
cilostazol could decrease the
intracranial hemorrhage volume and examine the protective mechanisms of
cilostazol. We evaluated the pre-treatment effects of the
antiplatelet drug cilostazol on the
collagenase-induced
intracranial hemorrhage volume and neurological outcomes in mice. To estimate the mechanism of
collagenase injury, we evaluated various vascular components in vitro, including endothelial cells, vascular smooth muscle cells, pericytes, and a blood-brain barrier model.
Cilostazol pre-treatment reduced the
intracranial hemorrhage volume with sufficient inhibition of platelet aggregation, and motor function was improved by
cilostazol treatment. Blood-brain barrier permeability was increased by
collagenase-induced
intracranial hemorrhage, and
cilostazol attenuated blood-brain barrier leakage.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling and western blot analysis showed that
cilostazol prevented pericyte cell death by inducing cyclic
adenosine monophosphate-responsive
element-
binding protein phosphorylation.
Cilostazol also prevented endothelial cell death and protected
collagen type 4,
laminin, and vascular endothelial- and
N-cadherins from
collagenase injury. In conclusion,
cilostazol reduced
collagenase-induced
intracranial hemorrhage volume by protecting the blood-brain barrier.